Table 1.
Baseline Characteristics and Outcomes for the PROFILE and Cambridge Cohorts
| Characteristic | PROFILE Discovery (n = 223)* |
PROFILE Validation (n = 223)† |
Cambridge Validation (n = 195)‡ |
|---|---|---|---|
| Age, yr, mean (SD) | 69.4 (8.2) | 70.8 (8.2) | 72.6 (7.7) |
| Male sex, n (%) | 179 (80.3) | 170 (76.2) | 142 (85.0) |
| Ever-smoker, n (%) | 163 (73.0) | 142 (63.7) | 153 (78.5) |
| Pulmonary function, mean (SD) | |||
| FVC% predicted | 75.5 (18.9) | 79.3 (18.9) | 77.2 (15.5) |
| DlCO% predicted | 43.5 (15.7) | 44.7 (14.6) | 50.1 (14.4) |
| Lung volume, L, mean (SD) | 4.02 (1.13) | 4.00 (1.01) | 3.97 (1.12) |
| Airway volume, L, mean (SD) | 0.02 (0.01) | 0.02 (0.01) | 0.07 (0.03) |
| Vascular volume, L, mean (SD) | 0.27 (0.10) | 0.25 (0.09) | 0.23 (0.08) |
| Fibrosis volume, L, mean (SD) | 0.63 (0.33) | 0.54 (0.26) | 0.57 (0.26) |
| Outcomes | |||
| 24-mo progression | 116 (52.0) | 101 (45.3) | NA |
| 60-mo mortality | 150 (67.3) | 127 (57.0) | 138 (70.8) |
Definition of abbreviation: PROFILE = Prospective Observation of Fibrosis in the Lung Clinical Endpoints.
*
Number missing: FVC, n = 2; DlCO, n = 11.
†
Number missing: FVC, n = 1; DlCO, n = 8.
‡
Number missing: FVC, n = 28; DlCO, n = 28.